# A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

> **NCT07431112** · PHASE1 · RECRUITING · sponsor: **AIRNA Corporation** · enrollment: 54 (estimated)

## Conditions studied

- Alpha 1 Antitrypsin Deficiency

## Interventions

- **DRUG:** AIR-001 SAD dose level 1
- **DRUG:** AIR-001 SAD dose level 2
- **DRUG:** AIR-001 SAD dose level 3
- **DRUG:** AIR-001 SAD dose level 4
- **DRUG:** AIR-001 MD dose level 1
- **DRUG:** AIR-001 MD dose level 2
- **DRUG:** AIR-001 MD dose level 3
- **DRUG:** AIR-001 MD dose level 4
- **DRUG:** AIR-001 MD dose level 5
- **DRUG:** AIR-001 MD dose level 6

## Key facts

- **NCT ID:** NCT07431112
- **Lead sponsor:** AIRNA Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2028-11
- **Final completion:** 2029-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431112, "A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07431112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*